NY-ESTEE-LAUDER
18.6.2020 15:41:12 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Michelle Freyre will join The Estée Lauder Companies as Senior Vice President, Global General Manager, Clinique, effective July 1, 2020. She will report to John Demsey, Executive Group President, The Estée Lauder Companies (ELC), and will succeed Jane Lauder, who has been appointed Executive Vice President, Enterprise Marketing and Chief Data Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005556/en/
In her new role leading Clinique, Michelle will be responsible for guiding the brand’s overall strategic vision, including innovation, product development and marketing, and all facets of consumer and digital engagement. She will partner closely with members of the global Clinique leadership team to continue brand momentum by driving consumer relevance globally and connecting emotionally with consumers throughout their beauty journey. Michelle and her team will also work to imagine the future of the retail experience, including Clinical Reality, Virtual Selling and High Touch services.
Michelle joins The Estée Lauder Companies from Johnson & Johnson, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of beauty brands at the time, including Neutrogena, Aveeno, Clean & Clear and RoC, and led the successful performance of many brands. Notably, she successfully transformed the image of Johnson & Johnson Beauty with a fully re-imagined Celebrity Talent & Influencer Strategy, diversifying the talent portfolio to reflect a more integrated approach.
“Michelle is a dynamic leader with deep experience across beauty, including marketing, innovation, sales, consumer engagement and strategic growth,” said Mr. Demsey. “She is particularly adept at finding new and innovative ways to fuel growth by exceeding consumer expectations and pushing the boundaries of possibility. She is a wonderful fit for Clinique, and I am thrilled to welcome her to the brand.”
Jane Lauder added, “I could not be happier that Michelle is joining Clinique. She has a tremendous track record of driving successful beauty brands, and her passion for surprising and delighting the global consumer is unparalleled. The Clinique team is lucky to have her as a leader, and I know the brand will be in wonderful hands with her at the helm.”
Prior to her role as President, U.S. Beauty, she served as the General Manager of Neutrogena, the largest brand within Johnson & Johnson’s Consumer division, and as the leader of the company’s Los Angeles campus. During her tenure, she strengthened brand leadership positions in facial care and sun care by focusing on core hero products and franchises and disruptive innovation across categories.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity, strengthening the talent pipeline at Johnson & Johnson with high-potential, diverse leaders. She has received several awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.” Additionally, she sits on the Board of Directors of Cynosure, LLC, and is a founding member of CHIEF, a private network designed to accelerate women in business and support women leaders.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005556/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 08:14:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer12.6.2026 08:00:00 CEST | Press release
Kazuhiko Nakayama appointed President and CEO of NTT DATA Group; Yutaka Sasaki to become Senior Executive Vice President of NTT, Inc. NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18. Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates. NTT DATA Group’s growth strategy will focus on two key areas alongside its core b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom